Cargando…

Erlotinib for advanced hepatocellular carcinoma: A systematic review of phase II/III clinical trials

OBJECTIVES: To evaluate the efficacy and safety of erlotinib for the treatment of advanced hepatocellular carcinoma (HCC). METHODS: A systematic literature search was undertaken in June 2015. Phase II/III trials of erlotinib for the treatment of advanced HCC were included. A descriptive analysis was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jing, Zong, Yuan, Xu, Gang-Zhu, Xing, Ke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Saudi Medical Journal 2016
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303794/ https://www.ncbi.nlm.nih.gov/pubmed/27761555 http://dx.doi.org/10.15537/smj.2016.11.16267

Ejemplares similares

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
por: Kaseb, Ahmed O, et al.
Publicado: (2016)

Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer
por: Cardin, Dana B, et al.
Publicado: (2014)

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
por: Yau, Thomas, et al.
Publicado: (2012)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)

Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review
por: Palermos, Dionysios, et al.
Publicado: (2022)

Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials
por: Bowling, Gartrell C., et al.
Publicado: (2023)

Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials
por: Fang, Ping, et al.
Publicado: (2012)

Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials
por: Bhagavathula, Akshaya Srikanth, et al.
Publicado: (2021)

Thymostimulin in advanced hepatocellular carcinoma: A phase II trial
por: Dollinger, Matthias M, et al.
Publicado: (2008)

Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials
por: Ricci, Claudio, et al.
Publicado: (2021)

An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer—A Systematic Review of Randomized Phase II and III Clinical Trials
por: Stanciu, Ioana-Miruna, et al.
Publicado: (2023)

Intermittent Chemotherapy and Erlotinib for Nonsmokers or Light Smokers with Advanced Adenocarcinoma of the Lung: A Phase II Clinical Trial
por: Zwitter, Matjaz, et al.
Publicado: (2011)

Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial
por: Lim, Sung Hee, et al.
Publicado: (2021)

A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
por: Han, Boram, et al.
Publicado: (2021)

Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma
por: Ronnebaum, Sarah, et al.
Publicado: (2021)

First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review
por: Zhang, Lan, et al.
Publicado: (2022)

Comparative Efficacy and Safety of Programmed Death-1 Pathway Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Network Meta-Analysis of Phase III Clinical Trials
por: da Silva, Laercio Lopes, et al.
Publicado: (2021)

Investigational Treatments in Phase I and II Clinical Trials: A Systematic Review in Asthma
por: Calzetta, Luigino, et al.
Publicado: (2022)

INST OX‐05‐024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial
por: Patt, Yehuda Z., et al.
Publicado: (2017)

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction
por: Wainberg, Z A, et al.
Publicado: (2011)

A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma
por: Lee, Dae-Won, et al.
Publicado: (2018)

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
por: Yang, J J, et al.
Publicado: (2017)

Tumour Burden Reporting in Phase III Clinical Trials of Metastatic Lung, Breast, and Colorectal Cancers: A Systematic Review
por: Santorsola, Mariachiara, et al.
Publicado: (2022)

Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response
por: Park, Semi, et al.
Publicado: (2013)

A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma
por: Zhao, Chuanhua, et al.
Publicado: (2016)

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
por: Deng, Wusheng, et al.
Publicado: (2022)

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
por: Mita, A C, et al.
Publicado: (2011)

Surveillance and diagnosis of hepatocellular carcinoma: A systematic review
por: Pascual, Sonia, et al.
Publicado: (2019)

Hepatocellular Carcinoma with Gastrointestinal Involvement: A Systematic Review
por: Urhut, Cristiana Marinela, et al.
Publicado: (2022)

Phase II Study to Topotecan and Cisplatin in Advanced Hepatocellular Carcinoma
por: Lee, Ga Young, et al.
Publicado: (2003)

Liver Transplantation for Pediatric Hepatocellular Carcinoma: A Systematic Review †
por: Kakos, Christos D., et al.
Publicado: (2022)

Artificial Intelligence in the Diagnosis of Hepatocellular Carcinoma: A Systematic Review
por: Martinino, Alessandro, et al.
Publicado: (2022)

A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer
por: Sanghvi, Samrat M., et al.
Publicado: (2022)

Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002–2022)
por: Sidali, Sabrina, et al.
Publicado: (2023)

Recurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic review
por: Araujo, Raphael L C, et al.
Publicado: (2017)

Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas
por: Qaddoumi, Ibrahim, et al.
Publicado: (2014)

Expression of genes that control core fucosylation in hepatocellular carcinoma: Systematic review
por: Norton, Pamela A, et al.
Publicado: (2019)

Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma
por: Barone, Michele, et al.
Publicado: (2019)

A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment
por: Yuen, Sydney C., et al.
Publicado: (2021)

Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis
por: Strzebonska, Karolina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6okg963ggls3u89sv1qsq1vc50